OncoGenex/Teva Alter Late-Stage Custirsen Program
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Teva and OncoGenex announced changes to the Phase III program of their prostate cancer drug custirsen on the heels of positive data from a competitor.
You may also be interested in...
Momentum In Prostate Cancer Therapy Moves Up To First-Line CRPC
The most recent events in the fast-evolving castration-resistant prostate cancer field illustrate how the major advances in therapy for patients who failed chemotherapy are now spreading to the larger population of CRPC patients receiving first-line therapy for metastatic disease. The upcoming year should see Phase III results from candidates ranging from a kinase inhibitor to an antisense agent.
Zytiga Study Supports Expansion To Early Patient Population
J&J halts Phase III trial of its prostate cancer drug six months early based on the recommendation of the trial’s independent data monitoring committee.
Prostate Cancer Market Snapshot: More Than Provenge
The launch of two drugs for metastatic prostate cancer this year – Dendreon Corp.'s Provenge (sipuleucel-T) and Sanofi-Aventis SA's Jevtana (cabazitaxel) – is shining a spotlight on an area of oncology that for many years was marked by a dearth of new treatment options.